Ross S B, Renyi A L
Acta Pharmacol Toxicol (Copenh). 1975;36(Suppl 5):395-408. doi: 10.1111/j.1600-0773.1975.tb00807.x.
The inhibition of the simultaneous uptake of 3-H-l-noradrenaline (NA) and 14-C-5-hydroxytryptamine (5-HT) in slices of the midbrain-hypothalamus region of the rat brain after oral administration of desipramine, imipramine, nortriptyline, amitriptyline, chlordesipramine and chlorimipramine was determined. All compounds were more active in inhibiting the NA uptake than the 5-HT uptake. This difference was very marked for desipramine, imipramine, nortriptyline and chlordesipramine. Chlorimipramine was almost as active on the 5-HT uptake (ED50 = 35 mg/kg orally) as on the NA uptake (ED50 = 20mg/kg orally) and amitriptyline had low activity on both uptake mechanisms (ED50 greater than 50 mg/kg orally). Desipramine and imipramine were the most active compounds on the NA uptake (ED50 = 8 mg/kg orally for both compounds) and the duration of the action was very long. The ED50 values for nortriptyline and chlordesipramine in inhibiting the NA uptake were about 20 mg/kg orally for both compounds. The inhibition of the 5-HT uptake was less than 50% at 50 mg/kg orally for all compounds except for imipramine (ED50 = 50 mg/kg orally) and for chlorimipramine. The role of the biotransformation for the inhibitory activities of imipramine, chlorimipramine and amitriptyline was investigated in animals pre-treated with SKF 525 A. The inhibitory potency of imipramine was increased by the same factor for both uptake mechanisms probably due to the large increase in the concentration of imipramine in the rat brain, which was demonstrated after the administration of 14-C-imipramine. The inhibitory activity of chlorimipramine was somewhat more increased for the5-HT uptake than for the NA uptake. The low activity of amitriptyline seems to be mainly due to poor resorption, since pretreatment of the animals with SKF 525 A only slightly increased the potency whereas intraperitoneal injection of amitriptyline had a rather marked effect on the NA uptake (ED50 = 11 mg/kg intraperitoneally).
测定了口服去甲丙咪嗪、丙咪嗪、去甲替林、阿米替林、氯去甲丙咪嗪和氯丙咪嗪后,大鼠脑内中脑-下丘脑区域切片中3-H-1-去甲肾上腺素(NA)和14-C-5-羟色胺(5-HT)同时摄取的抑制情况。所有化合物对NA摄取的抑制作用均强于对5-HT摄取的抑制作用。去甲丙咪嗪、丙咪嗪、去甲替林和氯去甲丙咪嗪的这种差异非常明显。氯丙咪嗪对5-HT摄取(口服ED50 = 35 mg/kg)的活性几乎与对NA摄取(口服ED50 = 20mg/kg)的活性相同,而阿米替林对两种摄取机制的活性均较低(口服ED50大于50 mg/kg)。去甲丙咪嗪和丙咪嗪对NA摄取的活性最高(两种化合物口服ED50均为8 mg/kg),且作用持续时间很长。去甲替林和氯去甲丙咪嗪抑制NA摄取的口服ED50值约为20 mg/kg。除丙咪嗪(口服ED50 = 50 mg/kg)和氯丙咪嗪外,所有化合物在口服50 mg/kg时对5-HT摄取的抑制率均低于50%。在预先用SKF 525 A处理的动物中,研究了生物转化对丙咪嗪、氯丙咪嗪和阿米替林抑制活性的作用。丙咪嗪对两种摄取机制的抑制效力增加的倍数相同,这可能是由于大鼠脑内丙咪嗪浓度大幅增加所致,这在给予14-C-丙咪嗪后得到证实。氯丙咪嗪对5-HT摄取的抑制活性比对NA摄取的抑制活性增加得更多。阿米替林活性较低似乎主要是由于吸收不良,因为用SKF 525 A预处理动物仅略微增加了效力,而腹腔注射阿米替林对NA摄取有相当明显的作用(腹腔注射ED50 = 11 mg/kg)。